pancreatic ductal adenocarcinoma – Discover Pharma

Welcome to Discover Pharma! Today is : October 12, 2026

pancreatic ductal adenocarcinoma

Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
L-glutamine shows 44% response rate in Phase 1 pancreatic cancer trial
L-glutamine combined with chemotherapy produced a 44% response rate in [...]

September 14, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
FDA grants Fast Track designation to Erasca pancreatic cancer drug
The FDA has granted Fast Track designation to Erasca’s investigational [...]

August 24, 2026
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Elicio misses Phase 2 endpoint but advances Phase 3 plan for pancreatic cancer immunotherapy
Elicio Therapeutics has reported that its Phase 2 Amplify-7P trial [...]

June 15, 2026
Advanced Therapies,Clinical & Regulatory,Therapeutic Areas
CuraCell reports pancreatic cancer findings from personalised TIL therapy programme
CuraCell TX has reported new findings supporting its personalised tumour-infiltrating [...]

June 8, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
NETRIS Pharma Nature publishes pancreatic cancer Phase 1b data showing NP137 survival and surgery gains
Nature publishes Phase 1b data showing NETRIS Pharma’s NP137 improves [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK